Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

---

Copy For Citation

Icli F., AKBULUT H., Utkan G., Yalcin B., Dincol D., Isikdogan A., ...More

JOURNAL OF SURGICAL ONCOLOGY, vol.95, no.6, pp.507-512, 2007 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 95 Issue: 6
• Publication Date: 2007
• Doi Number: 10.1002/jso.20728
• Journal Name: JOURNAL OF SURGICAL ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.507-512
• Keywords: advanced pancreatic carcinoma, low molecular weight heparin, cisplatin, gemcitabine, nadroparine, RECURRENT VENOUS THROMBOEMBOLISM, CELL LUNG-CANCER, RANDOMIZED-TRIAL, IN-VITRO, CARCINOMA, WARFARIN, SURVIVAL, PHASE, ANTICOAGULATION, CHEMOTHERAPY
• Lokman Hekim University Affiliated: No

Abstract

Background: In this non-randomized study we aimed to assess the efficacy of the addition of low molecular weight heparin (LMWH) to gemcitabine (GEM) plus cisplatinum (CDDP) combination chemotherapy on survival by prevention of thromboembolic complications in patients with advanced pancreatic cancer (APC).